What Terray Therapeutics does
Terray Therapeutics is an AI-native small-molecule drug discovery and development company that says it builds its advantage from integrating proprietary high-throughput experimentation with full-stack AI. On the AI side, Terray describes a foundation model (COATI) and an end-to-end platform it calls EMMI that includes molecule generation, potency/ADME prediction, and uncertainty-aware selection to decide what to synthesize next.
More
On the experimentation side, Terray emphasizes proprietary hardware (an ultra-dense microarray) and automated lab workflows, which it uses to iteratively generate large target–ligand interaction datasets and feed new data back into its models. Terray’s platform is presented as “chemistry-first, AI-native” and designed to work in the specific loop of small-molecule DMTA (design–make–test–analyze), with what it describes as a closed-loop workflow: AI proposes synthetically accessible molecules, predictive models characterize them in silico, and selection models quantify uncertainty to prioritize a small subset for lab testing. Terray states that this approach helps it identify and optimize novel starting points for hard-to-drug targets (including targets with no known chemistry starting point) and to accelerate iteration cycles in both its internal immunology-focused pipeline and partnered discovery programs. Terray’s externally visible business model is largely research collaboration: the company partners with biopharma companies to apply its platform (it references partners such as Bristol Myers Squibb, Gilead, and Calico) and also runs an internal pipeline (it highlights immune system disease programs).